It looks that way to me too. We know that Avita are currently...

It looks that way to me too. We know that Avita are currently looking to for new partners to distribute RECELL into the EU and AUS markets: "Plan to actively identify new distribution partners in major EU countries and Australia during remaining part of the year"

Given the complementary nature of BTM + RECELL + SUPRATHEL = improved standard of care, I think it would be a win-win situation for all parties but most importantly, the patients and clinicians. A couple of examples below for those interested:

BTM + RECELL case:
https://news.vumc.org/2023/11/21/young-patients-recovery-from-infection-multiple-amputations-moves-to-next-phase/
RECELL + SUPRATHEL study:
Comparative results of autologous skin cell suspension combined with a contact layer dressing versus autologous skin cell suspension and a poly-lactic acid dressing in larger total body surface burns

https://polynovo.com/polynovo-acquires-exclusive-sales-and-distribution-rights-for-suprathel-in-the-uk-australia-and-new-zealand/

The recent FDA approval of RECELL GO (new automated device which reduces the burden on hospital staff) and the anticipated CE Mark approval (which is recognised in Australia) of RECELL GO in September - December 2024, would make it easier for PNV's sales team to sell and add a new revenue stream for minimal outlay due to the synergies:

3/11/23 PolyNovo AGM 2023 - Webcast Recording [1:31:34]
DW: “Other partnerships that we’d be open to are people who bring some sort of technology that enhances our product, enhances the products we’ve got in our bag, you know, that we’re going to the same surgeons for”

Apologies for jumping the fence but I thought it the above may be interesting for some here.